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Cut off a tumor’s blood supply - it’s 
source of nutrients and growth 
factors - and the tumor should 
perish. EntreMed, Inc., of Rockville, 
Maryland, is one of many companies 
trying to put this simple theory of 
anti-angiogenesis into practice. By 
licensing anti-angiogenic molecules 
discovered by Judah Folkman 
(Children’s Hospital, Boston, 
Massachusetts), EntreMed has 
acquired perhaps the hottest intel- 
lectual property in cancer research 
today, and become the consummate 
middle-man. The company does the 
pre-clinical grunt-work for which 
Folkman does not have the time or 
resources, and provides the big 
pharmaceutical companies with drug 
candidates they cannot resist. 
lkenty five years in the wilderness 
Attacking angiogenesis, the process 
by which blood vessels sprout and 
invade new areas, was not always so 
popular. “When Folkman first 
proposed attacking cancer by 
inhibiting angiogenesis he was quite 
alone,” says Robert Auerbach 
(University of Madison, Wisconsin). 
“He recognized the importance of it 
and made it a real research goal. In 
that sense he’s a real pioneer.” 
Folkman first put forth his thesis 
in a 1971 article in the Neon, England 
Journal of Mea’icine. If angiogenesis is 
not switched on, said Folkman, a 
tumor will grow to be only the size of 
a pea. This state is maintained by 
balanced proliferation and cell death, 
until a combination of hypoxia, 
inactivation of tumor suppressor 
genes, and activation of tumor 
promoter genes results in the 
production of angiogenic molecules 
(candidates include basic fibroblast 
growth factor (bFGF) and vascular 
endothelial growth factor (VEGF)). 
Folkman went on to provide 
evidence for the importance of 
angiogenesis in tumor growth. But 
what he needed was a potent 
inhibitor - both to prove his theory 
and as a possible cancer cure. He 
characterized numerous inhibitors, 
including one from cartilage, one 
from the vitreous area of the eye, 
protamine, and various steroids. 
The most promising early 
compound was a re-discovered natural 
product called fumagillin (Table 1). 
But the first of Folkman’s potential 
drugs to attract the attention of 
EntreMed came from a database. 
Folkman and postdoctoral fellow 
Robert D’Amato thought about the 
possible side-effects of an anti- 
angiogenic drug and came up with 
two: problems with menstruation and 
birth defects (limb development may 
depend in part on the pathways laid 
down by blood vessels). Only six 
drugs in their database had both side- 
effects; the stand-out was thalidomide. 
Thalidomide was first used in 
Germany in 1957 as a sedative for 
mothers with morning sickness. In 
the next four years it was used in over 
40 countries, although it was rejected 
in the United States in 1961 by the 
Food and Drug Administration (FDA) 
Table 1 
because it also causes mild peripheral 
neuropathy. In that same year other 
countries began banning its use, but 
not before -12,000 babies were born 
with deformations including flipper- 
like arms and stumps for legs, 
In the same year that he reported 
on thalidomide’s activity, Folkman 
found that Z-methoxyestradiol and a 
protein called angiostatin were anti- 
angiogenic. Also in 1994, David 
Cheresh of Scripps Research Institute 
in La Jolla, California, found that 
integrin a,& was needed to mediate a 
survival signal for endothelial cells 
(which line blood vessels). 
Antagonists to IX,,& caused tumor 
regression in aivo, and are now in 
clinical trials (Table 1). 
Postdoctoral fellow Michael 
O’Reilly waded through over 40 liters 
of mouse urine to purify a few 
micrograms of angiostatin, using the 
strategy depicted in Figure 1. 
Surgeons had known for many years 
that removal of a primary tumor can 
cause secondary metastases to 
suddenly vascularize and enter a 
growth spurt. Folkman hypothesized 
that the primary tumor was producing 
a circulating anti-angiogenic factor, 
which would be found in the serum, 
or urine, of mice with primary tumors. 
The primary tumor might overcome 
the effect of the inhibitor(s) by 
making locally active angiogenic 
factors, which the metastases cannot 
yet produce. 
A partial list of companies interested in anti-angiogenesis therapies. 
Company Product 
TAP Holdings, Inc. 
British Biotech plc 
TNP-470, fumagillin derivative (pediatric phase I; adult phase Ill) 
Marimastat, a small molecule matrix metalloproteinase inhibitor 
(phase Ill) 
IXSYS, Inc. Humanized anti-cx$s-integrin antibody (finishing phase I) 
Merck Darmstadt Small molecule inhibitors of integrin o.Js (preclinical) 
Genentech, Inc. Anti-VEGF mononclonal antibody (phase I) 
SUGEN, Inc. Small molecule inhibitor of VEGF receptor Flk-l/KDR (phase I) 
Agouron Pharmaceuticals, Inc. Small molecule matrix metalloproteinase inhibitor (phase 111111); 
small molecule VEGF receptor inhibitor (preclinical) 
Repligen Corp. Small molecule inhibitors of bFGF and VEGF (preclinical) 
Boston Life Sciences, Inc. Troponin I (preclinical) 
Hybridon, Inc. Antisense VEGF (preclinical) 
NeXstar Pharmaceuticals, Inc. Aptamer antagonist of VEGF (preclinical) 
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Figure 1 
Strategy for isolating angiostatin. Primary 
tumors can suppress the development of 
metastases by producing a circulating factor. 
Serum or urine from mice bearing a primary 
tumor can substitute for the primary tumor in 
producing this result, and fractionation yields 
a pure protein, angiostatin, that has the 
same activity. 
Folkman’s latest and most exciting 
inhibitor, endostatin, was purified 
from an endothelial tumor cell line. 
Both protein inhibitors are fragments 
of larger proteins: angiostatin is 
derived from the blood-clotting 
protein plasminogen, and endostatin 
from collagen XVIII, a component of 
the extracellular matrix. 
A company for hire 
EntreMed is not called AngioMed 
because in 1991, the year it was 
founded, it was open to any good 
concept. “The basis for the 
company was that we would foster 
the growth of promising technology 
discovered at academic 
institutions,” says John Holaday, 
chief executive officer. Since 1994, 
the projects that EntreMed first 
licensed have taken a back seat to 
angiogenesis, although a cell perme- 
ation technology may enter phase I 
trials in the next year. EntreMed 
researchers will electroporate 
inositol hexaphosphate (IHP) into 
red blood cells so that the IHP 
binds hemoglobin. The altered 
hemoglobin can release three of its 
oxygen molecules (rather than just 
one) when it reaches an area low in 
oxygen, such as heart blood vessels 
during an attack of angina. 
The breakthrough for EntreMed 
came in October 1993, when the 
company signed a contract with 
Folkman and Children’s Hospital for 
rights to Folkman’s work in return for 
royalties and $2 million per year of 
research funding. At this stage 
Folkman had good evidence for 
thalidomide’s efficacy in mice, and 
was close to isolating angiostatin. 
Hoffmann-La Roche had decided 
against a collaboration with Folkman, 
but meanwhile D’Amato (who.did the 
thalidomide work) had been talking 
to Holaday, his mentor from an earlier 
time at Walter Reed Army Institute of 
Research in Washington, D.C. “Life 
is a process of personal relationships,” 
says Holaday, and this personal 
relationship gave his company a focus. 
A cash infusion came in late 1995 
from Bristol-Myers Squibb, when 
EntreMed had only 60 days of 
money in hand. Thalidomide trials 
sponsored by the two companies and 
the National Cancer Institute began 
in April 1996, and on the strength of 
this work EntreMed went public. 
Interim results of the phase II 
thalidomide trials are promising: a 
50% response rate for glioblastomas, 
gliomas and Kaposi’s sarcoma. Phase 
II trials of thalidomide for age- 
related macular degeneration are also 
underway, as this form of adult-onset 
blindness is characterized by 
excessive blood vessel growth in the 
retina. If thalidomide is effective, its 
approval process may be reasonably 
straightforward. Stringent safety 
guidelines have already been worked 
out by Celgene Corp. (Warren, New 
Jersey), who are awaiting final FDA 
approval of thalidomide for the 
treatment of leprosy sores. 
Bring on the big guns 
Thalidomide may, however, be 
merely a warm-up for the protein 
inhibitors angiostatin and endostatin. 
EntreMed has now produced active 
human proteins from cultures of the 
yeast Pichiapastoris, and trials may 
begin in 1999. 
The most spectacular preclinical 
data have come from endostatin. In 
the 27 November 1997 issue of Nature, 
Folkman reported that endostatin 
could repeatedly shrink tumors. Once 
the tumors shrank, Folkman stopped 
endostatin treatment, restarting only 
when the tumors had re-grown to 
l-Z% of total body mass. Each round 
of shrinkage occurred at the same rate, 
suggesting that the genetically stable 
endothelial cells do not become drug 
resistant. After 2-6 repetitions, 
depending on the cancer type, the 
cancers failed to grow back at all. 
“We were pleasantly surprised [by 
these results],” says Edward Gubish, 
EntreMed’s vice president for 
research. The high rate of endothelial 
cell turnover in tumors may explain 
why endostatin can shrink tumors 
rather than just halt their growth. “It 
could be the Hayflick experiment in 
uiuo,” says Craig Crews of Yale 
University. “The endothelial cells 
may have senesced.” Alternatively, 
regrowth of new cells may be halted 
by increasing amounts of inhibitor, 
which may accumulate in the matrix 
as the endothelial cells remodel their 
surroundings. 
EntreMed’s weakness is that it 
doesn’t know the precise mechanism 
of action for any of its three leading 
drug candidates, which makes the 
FDA approval process and the design 
of analogs more challenging. It also 
has many competitors, although some 
‘of the drugs proposed by these com- 
panies suffer from a lack of specificity 
(the broad spectrum matrix metallo- 
proteinase inhibitors) or the possibility 
of drug resistance (tumors may make 
alternative angiogenic molecules when 
others such as VEGF are blocked). 
If Folkman’s proteins can make 
the leap from mice to humans his 
early vision will find ultimate 
vindication. “Folkman was fighting 
against a whole line of thinking: that 
you have to kill all the cancer cells 
directly,” says Cheresh. Instead, he 
proposed that killing the support cells 
would work. “I think he is right,” 
says Cheresh. “I think it is possible.” 
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